+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Open pilot study of the addition of sulfasalazine to methotrexate in patients with rheumatoid arthritis inadequately controlled with methotrexate alone



Open pilot study of the addition of sulfasalazine to methotrexate in patients with rheumatoid arthritis inadequately controlled with methotrexate alone



Journal of Clinical Rheumatology 2(5): 244-250



The safety and efficacy of the sequential addition of sulfasalazine to baseline methotrexate was assessed in patients with active rheumatoid arthritis inadequately controlled by methotrexate alone. Nineteen patients were recruited in a pilot, prospective, open label, uncontrolled clinical trial. One patient was lost to follow-up, four dropped out due to toxicity, one dropped out due to inefficacy, and five violated the protocol. A modified intent-to-treat analysis was performed by carrying forward the clinical data before drop-out or protocol violation to the final visit for the 18 evaluable patients. Swollen and tender joint counts, physicians's and patient's global scores were significantly improved (p < 0.021 to 0.001). Forty-two percent of patients (8/19) demonstrated >/= 20% improvement and 26% (5/19) showed >/= 50% improvement in 4 or more clinical parameters at 6 month's follow-up. Rheumatoid factor negative patients were more likely (p < 0.025) to complete the trial. A controlled clinical trial will be necessary to determine the effectiveness of this combination and the value of sequential addition chemotherapy in patients with recalcitrant rheumatoid arthritis.

(PDF emailed within 0-6 h: $19.90)

Accession: 054754918

Download citation: RISBibTeXText

PMID: 19078078

DOI: 10.1097/00124743-199610000-00003


Related references

Addition of sulfasalazine to rheumatoid arthritis patients inadequately controlled with methotrexate. Arthritis & Rheumatism 38(9 SUPPL ): S367, 1995

Comparative efficacy and safety of TNF-inhibitor plus methotrexate versus oral triple therapy in patients with active rheumatoid arthritis inadequately responding to methotrexate: A meta-analysis of randomized controlled trials. International Journal of Clinical Pharmacology and Therapeutics 56(6): 263-269, 2018

Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Annals of the Rheumatic Diseases 66(2): 235-241, 2006

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Annals of the Rheumatic Diseases 72(12): 1927-1933, 2014

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 46(5): 1164-1170, 2002

SAT0173Baseline Parameters Identified in Early, Methotrexate-Nave Rheumatoid Arthritis Patients with Better Outcomes with Certolizumab Pegol+Methotrexate Compared to Placebo+Methotrexate: Post-Hoc Analyses of C-OPERA, A Randomized, Controlled, Phase 3 Study. Annals of the Rheumatic Diseases 74(Suppl 2): 716.2-717, 2015

Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis. Terapevticheskii Arkhiv 80(5): 25-30, 2008

OP0155Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality of life results of the randomised, controlled swefot trial. Annals of the Rheumatic Diseases 71(Suppl 3): 106.2-106, 2013

Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. Journal of Rheumatology 39(4): 720-727, 2013

Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Modern Rheumatology 24(3): 410-418, 2015

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374(9688): 459-466, 2009

Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clinical and Experimental Rheumatology 25(6): 838-846, 2008

A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. Journal of the Formosan Medical Association 103(8): 618-623, 2004

Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. Journal of Rheumatology 29(5): 883-889, 2002

Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial. Modern Rheumatology 24(4): 561-566, 2015